Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Invion ( (AU:IVX) ).
Invion Limited has confirmed that it received an Orphan Drug Designation from the U.S. FDA for anal cancer, which is expected to have a material effect on the company’s securities. The company became aware of the designation on 19 August 2025 and promptly took steps to verify the information and communicate with the ASX. Invion assures compliance with ASX Listing Rules and has authorized the disclosure of this information by its board.
More about Invion
Invion is a life-science company focused on the global research and development of Photosoft™ technology for treating various cancers, atherosclerosis, and infectious diseases. The company holds exclusive licensing and distribution rights in several regions, including Australia, New Zealand, and parts of Asia Pacific, for different medical indications. Invion’s research and clinical trials are funded by RMW Cho Group Limited, and it is listed on the ASX.
Average Trading Volume: 162,154
Technical Sentiment Signal: Sell
Current Market Cap: A$9.85M
Find detailed analytics on IVX stock on TipRanks’ Stock Analysis page.